APRE
Aprea Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.08M
P/E Ratio
—
EPS
$-1.99
Beta
1.52
52W High
$2.22
52W Low
$0.55
50-Day MA
$0.82
200-Day MA
$1.15
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 285,760 |
| Gross Profit (TTM) | $-6.76M |
| EBITDA | $-13.21M |
| Operating Margin | -79206.00% |
| Return on Equity | -74.60% |
| Return on Assets | -41.40% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $1.52 |
| Price-to-Book | 0.79 |
| Price-to-Sales (TTM) | 35.26 |
| EV/Revenue | - |
| EV/EBITDA | 0.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -98.40% |
| Shares Outstanding | $11.98M |
| Float | $7.76M |
| % Insiders | 11.55% |
| % Institutions | 18.90% |
Historical Volatility
HV 10-Day
79.33%
HV 20-Day
117.25%
HV 30-Day
108.08%
HV 60-Day
103.06%
HV Rank
86.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.40 target)
1
Strong Buy2
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026